

HR 2244

Patient Experience in Research Act of 2017

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Apr 28, 2017

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (May 5, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/2244>

Sponsor

Name: Rep. Lance, Leonard [R-NJ-7]

Party: Republican • **State:** NJ • **Chamber:** House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. DeGette, Diana [D-CO-1]	D · CO		Apr 28, 2017
Rep. Clarke, Yvette D. [D-NY-9]	D · NY		May 22, 2017
Rep. Eshoo, Anna G. [D-CA-18]	D · CA		May 22, 2017

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 5, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Apr 28, 2017)

Patient Experience in Research Act of 2017

This bill requires the Food and Drug Administration to carry out a pilot project under which sponsors of new drugs or biological products agree to evaluate: (1) the distress experienced by patients in clinical trials for medications intended to treat a serious condition, and (2) the effects of providing support to distressed patients on the outcome of a clinical trial.

The user fee is waived for new drug applications that include data from such an evaluation.

Actions Timeline

- **May 5, 2017:** Referred to the Subcommittee on Health.
- **Apr 28, 2017:** Introduced in House
- **Apr 28, 2017:** Referred to the House Committee on Energy and Commerce.